HC Wainwright Cuts Earnings Estimates for Oncolytics Biotech

Oncolytics Biotech Inc. (NASDAQ:ONCY) – Investment analysts at HC Wainwright cut their FY2029 earnings per share (EPS) estimates for shares of Oncolytics Biotech in a research note issued on Monday, March 10th. HC Wainwright analyst P. Trucchio now anticipates that the company will post earnings of $0.73 per share for the year, down from their previous estimate of $0.75. HC Wainwright currently has a “Buy” rating and a $5.00 target price on the stock. The consensus estimate for Oncolytics Biotech’s current full-year earnings is ($0.28) per share.

Other equities analysts have also recently issued research reports about the company. Leede Financial cut Oncolytics Biotech from a “strong-buy” rating to a “moderate buy” rating in a report on Wednesday, November 13th. Raymond James upgraded Oncolytics Biotech to a “moderate buy” rating in a report on Thursday, November 14th. Royal Bank of Canada cut their price objective on Oncolytics Biotech from $6.00 to $5.00 and set an “outperform” rating on the stock in a report on Monday. Finally, Maxim Group cut their price objective on Oncolytics Biotech from $5.00 to $3.00 and set a “buy” rating on the stock in a report on Monday. Three analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has an average rating of “Buy” and an average price target of $4.00.

Oncolytics Biotech Trading Down 4.6 %

Oncolytics Biotech stock opened at $0.61 on Wednesday. Oncolytics Biotech has a 1 year low of $0.58 and a 1 year high of $1.53. The firm has a market capitalization of $52.38 million, a P/E ratio of -2.27 and a beta of 1.18. The business has a 50-day moving average of $0.77 and a 200-day moving average of $0.93.

Institutional Investors Weigh In On Oncolytics Biotech

Several institutional investors have recently bought and sold shares of ONCY. Geode Capital Management LLC raised its stake in shares of Oncolytics Biotech by 59.6% during the 4th quarter. Geode Capital Management LLC now owns 66,939 shares of the company’s stock worth $61,000 after purchasing an additional 24,997 shares in the last quarter. International Assets Investment Management LLC raised its stake in shares of Oncolytics Biotech by 15.0% during the 4th quarter. International Assets Investment Management LLC now owns 200,400 shares of the company’s stock worth $186,000 after purchasing an additional 26,069 shares in the last quarter. Vantage Point Financial LLC bought a new stake in shares of Oncolytics Biotech during the 4th quarter worth approximately $27,000. National Bank of Canada FI raised its stake in shares of Oncolytics Biotech by 199.6% during the 4th quarter. National Bank of Canada FI now owns 64,479 shares of the company’s stock worth $60,000 after purchasing an additional 42,955 shares in the last quarter. Finally, Virtu Financial LLC bought a new stake in shares of Oncolytics Biotech during the 4th quarter worth approximately $90,000. Institutional investors own 6.82% of the company’s stock.

Oncolytics Biotech Company Profile

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.